tradingkey.logo
tradingkey.logo
Suchen

Haemonetics Corp

HAE
Zur Watchlist hinzufügen
74.860USD
-0.140-0.19%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
3.39BMarktkapitalisierung
36.30KGV TTM

mehr Informationen über Haemonetics Corp Unternehmen

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

Haemonetics Corp Informationen

BörsenkürzelHAE
Name des UnternehmensHaemonetics Corp
IPO-datumOct 17, 1979
CEOSimon (Christopher A)
Anzahl der mitarbeiter3023
WertpapierartOrdinary Share
GeschäftsjahresendeOct 17
Addresse125 Summer Street
StadtBOSTON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl02110
Telefon17818487100
Websitehttps://www.haemonetics.com
BörsenkürzelHAE
IPO-datumOct 17, 1979
CEOSimon (Christopher A)

Führungskräfte von Haemonetics Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Laurie A. Miller
Ms. Laurie A. Miller
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
40.07K
-0.78%
Ms. Michelle L. Basil, J.D.
Ms. Michelle L. Basil, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
34.51K
+10.58%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
25.04K
--
Mr. Robert E. Abernathy
Mr. Robert E. Abernathy
Independent Director
Independent Director
24.98K
--
Dr. Mark W. Kroll, Ph.D.
Dr. Mark W. Kroll, Ph.D.
Independent Director
Independent Director
23.36K
-5.99%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Chairman of the Board
Independent Chairman of the Board
19.37K
--
Mr. Michael J. Coyle
Mr. Michael J. Coyle
Independent Director
Independent Director
15.39K
--
Ms. Diane M. Bryant
Ms. Diane M. Bryant
Independent Director
Independent Director
7.13K
--
Mr. Roy Galvin
Mr. Roy Galvin
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
7.00K
+53.66%
Mr. Christopher A. Simon
Mr. Christopher A. Simon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Laurie A. Miller
Ms. Laurie A. Miller
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
40.07K
-0.78%
Ms. Michelle L. Basil, J.D.
Ms. Michelle L. Basil, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
34.51K
+10.58%
Mr. Charles J. Dockendorff, CPA
Mr. Charles J. Dockendorff, CPA
Independent Director
Independent Director
25.04K
--
Mr. Robert E. Abernathy
Mr. Robert E. Abernathy
Independent Director
Independent Director
24.98K
--
Dr. Mark W. Kroll, Ph.D.
Dr. Mark W. Kroll, Ph.D.
Independent Director
Independent Director
23.36K
-5.99%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Chairman of the Board
Independent Chairman of the Board
19.37K
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Haemonetics Corp?

Die fünf größten Anteilseigner von Haemonetics Corp sind: Ms. Laurie A. Miller

Wie viele Institutionen halten Anteile an Haemonetics Corp (HAE)?

Mit Stand vom 2026Q1 halten 737 Institutionen Anteile an Haemonetics Corp, mit einem Gesamtmarktwert von etwa 58.91M, was 126.77% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 664078.00 gestiegen.